Home › Companies › PMV PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and PMV PHARMACEUTICALS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 6, 2024: 4 items on PMV PHARMACEUTICALS INC.’s Form 8-K, filed June 7, 2024: 2 elected · 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore PMV PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are PMV PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kirsten Flowers | 35,683,498 | -- | -- | 656,260 | 7,211,791 | 98% | Elected | — |
| Elect Director: Carol Gallagher, Pharm.D. | 27,082,825 | -- | -- | 9,256,933 | 7,211,791 | 75% | Elected | — |
| 2. Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers | 34,452,101 | 1,079,423 | 808,234 | -- | 7,211,791 | 97% | Approved | — |
| 3. Ratification of Independent Registered Public Accounting Firm | 43,460,392 | 90,902 | 255 | -- | -- | 99.7% | Approved | — |
Source: PMV PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
Each item below shows how the 111 asset managers that disclosed a PMV PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Carol Gallagher, Pharm.D.
PMV PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carol Gallagher, Pharm.D.”): 27,082,825 for, 9,256,933 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the two persons listed below as Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective directo…”
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 45 asset managers below reported 6,324,882 for, 1,165,037 withheld, 24,965 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,428,434 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,208,896 | 0 | 0 | 0 | For |
| Fidelity | 845,206 | 0 | 0 | 6,800 | For |
| BlackRock | 837,266 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 364,929 | Withhold |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 329,949 | Withhold |
| SEI | 292,450 | 0 | 0 | 0 | For |
| Charles Schwab | 266,049 | 0 | 0 | 0 | For |
| Equitable | 71,804 | 0 | 0 | 50,500 | Mixed |
| Dimensional | 0 | 0 | 0 | 103,261 | Withhold |
| TIAA | 91,943 | 0 | 0 | 0 | For |
| Nationwide | 1,483 | 0 | 0 | 82,944 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 67,477 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 55,500 | Withhold |
| American Century | 0 | 0 | 0 | 50,087 | Withhold |
| Columbia Threadneedle | 49,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,400 | 0 | 0 | 6,343 | Mixed |
| T. Rowe Price | 36,376 | 0 | 0 | 0 | For |
| Northern Trust | 21,628 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 20,217 | Withhold |
| GuideStone | 0 | 0 | 0 | 17,857 | Withhold |
| AQR | 0 | 0 | 0 | 16,577 | Withhold |
| Jackson National | 0 | 0 | 16,475 | 0 | Abstain |
| Bridge Builder Trust | 15,929 | 0 | 0 | 0 | For |
| Pacific Life | 15,134 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Kirsten Flowers
PMV PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kirsten Flowers”): 35,683,498 for, 656,260 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the two persons listed below as Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective directo…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 45 asset managers below reported 7,333,166 for, 163,435 withheld, 18,283 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,428,434 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,208,896 | 0 | 0 | 0 | For |
| Fidelity | 852,006 | 0 | 0 | 0 | For |
| BlackRock | 837,266 | 0 | 0 | 0 | For |
| Goldman Sachs | 364,929 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 329,949 | 0 | 0 | 0 | For |
| SEI | 292,450 | 0 | 0 | 0 | For |
| Charles Schwab | 266,049 | 0 | 0 | 0 | For |
| Equitable | 71,804 | 0 | 0 | 50,500 | Mixed |
| Dimensional | 0 | 0 | 0 | 103,261 | Withhold |
| TIAA | 91,943 | 0 | 0 | 0 | For |
| Nationwide | 84,427 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 67,477 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 55,500 | 0 | 0 | 0 | For |
| American Century | 50,087 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,400 | 0 | 0 | 6,343 | Mixed |
| T. Rowe Price | 36,376 | 0 | 0 | 0 | For |
| Northern Trust | 21,628 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,217 | 0 | 0 | 0 | For |
| GuideStone | 17,857 | 0 | 0 | 0 | For |
| AQR | 16,577 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 16,475 | 0 | Abstain |
| Bridge Builder Trust | 15,929 | 0 | 0 | 0 | For |
| Pacific Life | 15,134 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Combines 7 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
PMV PHARMACEUTICALS INC.’s own tally for this item (“2. Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers”): 34,452,101 for, 1,079,423 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company's definitive proxy statement on Schedule 14A, filed…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,428,434 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,208,896 | 0 | 0 | 0 | For |
| Fidelity | 852,006 | 0 | 0 | 0 | For |
| BlackRock | 837,266 | 0 | 0 | 0 | For |
| Goldman Sachs | 364,929 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 329,949 | 0 | 0 | 0 | For |
| SEI | 292,450 | 0 | 0 | 0 | For |
| Charles Schwab | 266,049 | 0 | 0 | 0 | For |
| Equitable | 122,304 | 0 | 0 | 0 | For |
| Dimensional | 0 | 103,261 | 0 | 0 | Against |
| TIAA | 91,943 | 0 | 0 | 0 | For |
| Nationwide | 84,427 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 67,477 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 55,500 | 0 | 0 | Against |
| American Century | 0 | 50,087 | 0 | 0 | Against |
| Columbia Threadneedle | 49,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,400 | 6,343 | 0 | 0 | Mixed |
| T. Rowe Price | 36,376 | 0 | 0 | 0 | For |
| Northern Trust | 21,628 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,217 | 0 | 0 | 0 | For |
| GuideStone | 17,857 | 0 | 0 | 0 | For |
| AQR | 16,577 | 0 | 0 | 0 | For |
| Jackson National | 0 | 16,475 | 0 | 0 | Against |
| Bridge Builder Trust | 15,929 | 0 | 0 | 0 | For |
| Pacific Life | 15,134 | 0 | 0 | 0 | For |
Fund voting reports, all 45 managers: 7,274,307 for, 240,577 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 6,475,291 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 2,419,625 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 1,275,462 | 0 | 0 | 0 | For |
| Citadel | 1,240,158 | 0 | 0 | 0 | For |
| BlackRock | 1,173,938 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 903,137 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 868,385 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 860,910 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 820,500 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 758,094 | 0 | 0 | 0 | For |
| DE Shaw | 756,917 | 0 | 0 | 0 | For |
| State Street | 749,601 | 57 | 0 | 0 | For |
| Two Sigma | 644,032 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 566,879 | 0 | 0 | 0 | For |
| Opaleye Management Inc. | 450,000 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 328,640 | 0 | 0 | 0 | For |
| SEI | 308,196 | 0 | 0 | 0 | For |
| Goldman Sachs | 291,723 | 0 | 0 | 0 | For |
| Charles Schwab | 266,131 | 0 | 0 | 0 | For |
| Point72 | 214,841 | 0 | 0 | 0 | For |
| Northern Trust | 211,872 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 155,175 | 0 | 0 | 0 | For |
| AQR | 138,217 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 131,845 | 0 | 0 | Against |
| Dimensional | 0 | 95,048 | 0 | 0 | Against |
Institutional-manager reports, all 81 managers: 22,387,962 for, 457,366 against, 62 abstained. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT PUBLIC ACCOUNTING FIRM.
PMV PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of Independent Registered Public Accounting Firm”): 43,460,392 for, 90,902 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 45 asset managers below reported 7,514,884 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,428,434 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 1,208,896 | 0 | 0 | 0 | For |
| Fidelity | 852,006 | 0 | 0 | 0 | For |
| BlackRock | 837,266 | 0 | 0 | 0 | For |
| Goldman Sachs | 364,929 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 329,949 | 0 | 0 | 0 | For |
| SEI | 292,450 | 0 | 0 | 0 | For |
| Charles Schwab | 266,049 | 0 | 0 | 0 | For |
| Equitable | 122,304 | 0 | 0 | 0 | For |
| Dimensional | 103,261 | 0 | 0 | 0 | For |
| TIAA | 91,943 | 0 | 0 | 0 | For |
| Nationwide | 84,427 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 67,477 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 55,500 | 0 | 0 | 0 | For |
| American Century | 50,087 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,794 | 0 | 0 | 0 | For |
| Lincoln Financial | 38,743 | 0 | 0 | 0 | For |
| T. Rowe Price | 36,376 | 0 | 0 | 0 | For |
| Northern Trust | 21,628 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,217 | 0 | 0 | 0 | For |
| GuideStone | 17,857 | 0 | 0 | 0 | For |
| AQR | 16,577 | 0 | 0 | 0 | For |
| Jackson National | 16,475 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 15,929 | 0 | 0 | 0 | For |
| Pacific Life | 15,134 | 0 | 0 | 0 | For |
Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,443,488 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.72% |
| 2 | MERIDIAN FUND INC | 2.35% |
| 3 | Fidelity | 1.66% |
| 4 | BlackRock | 1.63% |
| 5 | Goldman Sachs | 0.71% |
| 6 | Advantage Advisers Xanthus Fund, L.L.C. | 0.64% |
| 7 | SEI | 0.57% |
| 8 | Charles Schwab | 0.52% |
| 9 | Equitable | 0.24% |
| 10 | Dimensional | 0.20% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 12.59% |
| 2 | ArrowMark Colorado Holdings LLC | 4.70% |
| 3 | PFM Health Sciences, LP | 2.48% |
| 4 | Citadel | 2.41% |
| 5 | BlackRock | 2.28% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.76% |
| 7 | ACADIAN ASSET MANAGEMENT LLC | 1.69% |
| 8 | ALKEON CAPITAL MANAGEMENT LLC | 1.67% |
| 9 | Ensign Peak Advisors, Inc | 1.59% |
| 10 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1.47% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with OrbiMed Advisors | 12.76% | DEF14A |
| Entities affiliated with BlackRock, Inc. | 6.28% | DEF14A |
| ArrowMark Colorado Holdings, LLC | 5.28% | DEF14A |
| Vanguard Group | 4.20% | 13F |
| David H. Mack, Ph.D. | 4.18% | DEF14A |
| BlackRock | 2.15% | 13F |
| Geode Capital | 1.76% | 13F |
| State Street | 1.53% | 13F |
| D.E. Shaw | 1.40% | 13F |
| Millennium Management | 1.27% | 13F |
Percentages above are of 51,443,488 shares outstanding, as reported by PMV PHARMACEUTICALS INC. on its Form 10-Q dated May 8, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PMV PHARMACEUTICALS INC.’s 10-Q dated May 8, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At PMV PHARMACEUTICALS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 111 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 611 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — PMV PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PMV PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
PMV PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page).
Download data (CSV): ballot items · votes by manager · column guide.